10-K/A: Regulus Therapeutics Files Amendment to 10-K to Include Omitted Information

Regulus Therapeutics files an amendment to its annual report on Form 10-K to include information required in Part III, which was not initially included due to the delay in filing the definitive proxy statement.

Summary

• Regulus Therapeutics Inc. is filing Amendment No. 1 on Form 10-K/A to its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
• The amendment provides information required by Part III of the Original Filing, which was not included because the company does not intend to file its definitive proxy statement within 120 days of the end of the fiscal year.
• New certifications by the principal executive and principal financial officers are included.
• No financial statements are included in this amendment, and no changes have been made to Items 307 and 308 of Regulation S-K.
• The original filing continues to speak as of the date of the original filing, and the disclosures have not been updated to reflect any events which occurred at a date subsequent to the filing of the Original Filing other than as expressly indicated in this Amendment.
• The document includes information about the company's directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, and accounting fees.

Sentiment

Score: 6

Explanation: The document is primarily factual and descriptive, with a neutral tone. The amendment itself suggests a minor administrative oversight, but the overall content does not indicate significant positive or negative sentiment.

Positives

• The company has a well-defined Code of Business Conduct and Ethics.
• The company has an Insider Trading and Window Period Policy to promote compliance with insider trading laws.
• The company's executive compensation program is designed to reward achievement of strategic goals and create long-term value for stockholders.
• The company has a written related-person transactions policy to ensure fair dealings.
• The Board of Directors has determined that all directors, except for Mr. Hagan and Dr. Klassen, are independent.

Negatives

• The company did not initially include all required information in its original Form 10-K filing, necessitating this amendment.
• The company does not intend to file its definitive proxy statement within 120 days of the end of the fiscal year ended December 31, 2024.

Risks

• The document mentions forward-looking statements that are subject to risks and uncertainties, which could cause actual results to differ materially from those anticipated.
• The company's success depends on the achievement of specific strategic goals, and failure to achieve these goals could negatively impact the company's performance.
• The company's financial performance is subject to various risks, including those discussed in the Original Filing.

Future Outlook

The document includes forward-looking statements regarding the company's future plans, strategies, intentions, expectations, objectives, goals, or prospects, which are subject to risks and uncertainties.

Management Comments

• The Compensation Committee uses its judgment to establish a total compensation program for each Named Executive Officer that is a mix of current, short-term and long-term incentive compensation, and cash and non-cash compensation, that it believes appropriate to achieve the goals of our executive compensation program and our corporate objectives.
• In line with our pay for performance philosophy, we structured a significant portion of our Named Executive Officers 2024 compensation to be variable, at risk and tied directly to our measurable performance in the form of performance-based bonuses and equity incentives.

Industry Context

The document provides information about a biopharmaceutical company, Regulus Therapeutics, and its operations, which are relevant to the biotechnology and healthcare industries.

Comparison to Industry Standards

• The document mentions that the Compensation Committee reviewed market data from Aon/Radford to determine 2024 base salaries of the NEOs.
• The document mentions that the Board of Directors made a recommendation following analysis and recommendations by Aon concerning the total options held by our directors as compared with the Company's peers as a percentage of the Company.

Related Party Transactions

• The document discloses transactions with related persons, including directors and holders of more than 5% of the company's common stock, in connection with private placement financings.
• Federated Hermes Kaufmann Funds, Entities affiliated with New Enterprise Associates, Inc., DAFNA Life Science Funds and Stelios Papadopoulos, Ph.D. participated in the 2024 Private Placement.
• Federated Hermes Kaufmann Funds, Entities affiliated with New Enterprise Associates, Inc. and Stelios Papadopoulos, Ph.D. participated in the 2023 Private Placement.

Stakeholder Impact

• The information in the amendment is relevant to shareholders, as it provides details about the company's directors, executive compensation, and corporate governance.
• The company's employees are affected by the executive compensation program and equity incentive plans.
• The company's customers and partners may be interested in the company's business strategy and clinical development programs.

Next Steps

• The company will continue to execute its business strategy and advance its clinical and preclinical programs.
• The company will file its definitive proxy statement at a later date.
• The company will continue to monitor and comply with SEC rules and regulations.

Key Dates

Keywords

Regulus Therapeutics, Form 10-K, Amendment, Directors, Executive Compensation, Corporate Governance, Securities, Stock Options, Financial Reporting, Biopharmaceutical